Anlon Healthcare Expands to Nigeria for West Africa Growth

Anlon Healthcare has formally incorporated a new subsidiary named Anlon Healthcare Nigeria on September 20, 2026. This strategic move directly supports the corporate long-term growth objective by establishing a direct foothold in the region.

Key Operational Scope and Regional Reach

The new subsidiary is structured to handle a wide array of activities across pharmaceutical and personal care sectors. The operational mandate includes:

• Manufacturing, importing, processing, producing, and trading active pharmaceutical ingredients and pharmaceutical bulk drugs.
• Handling intermediates and finished dosage formulations for human use, alongside cosmetic and personal care products.
• Producing surgical implants and medical devices for the regional market.
• Providing direct access to 16 Western African countries via the local entity.

Shareholding Structure and Core Business

The parent company maintains a commanding stake in the newly formed international venture to consolidate its operational reach. The ownership breakdown and foundational business profile include:

• Holding 90% of the share capital in the subsidiary.
• Owning 90 million equity shares at a face value of Naira 1 each.
• Operating primarily as a chemical manufacturing company supplying pharmaceutical intermediates and APIs to domestic and international customers.

By leveraging this local entity, Anlon Healthcare intends to strategically complement and expand its existing business operations within the West African market.